Stockpolly
Search
TLPH · NASDAQ · Drug Manufacturers - Specialty & Generic

Talphera (TLPH)

Develops hospital and dialysis therapies, led by Niyad for renal-replacement anticoagulation.

$1.20
At close+0.02 (+1.69%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000000000000
Cost of revenue121221100000
Gross profit−1−1−1−2−2−1−100000
233222243344
Research & development121221122222
000000022222
General & administrative000000000002
Other expenses111000100000
Operating income−3−4−4−4−4−3−3−4−3−3−4−4
20000100−1010
Interest income200000000000
Interest expense000000000000
Other non-operating income000−10−10010−1−1
Income before tax−1−5−4−4−3−2−3−3−4−4−3−4
Income tax expense000000000000
Net income from continuing operations−1−5−4−4−3−2−3−3−4−4−3−4
Discontinued operations000000000000
Net income−1−5−4−4−3−2−3−3−4−4−3−4
EPS, basic−$0.08−$0.25−$0.16−$0.15−$0.13−$0.07−$0.10−$0.10−$0.11−$0.09−$0.06−$0.06
EPS, diluted−$0.08−$0.25−$0.16−$0.15−$0.13−$0.07−$0.10−$0.10−$0.11−$0.09−$0.06−$0.06
Weighted average shares, basic171825262626263541424276
Weighted average shares, diluted171825262626263541424276
EBITDA−3−5−4−4−3−20−3−4−4−3−3
Depreciation & amortization000000300000
EBIT−3−5−4−4−3−2−3−3−4−4−3−3